Background: Patients admitted with autoimmune thrombocytopenic purpura (ITP) tend to be high-risk individuals, primarily because of their susceptibility to bleeding and the constraints on potential medical interventions. Heart failure (HF) is a complex and widespread condition that significantly impairs quality of life. These patients face a multitude of respiratory and cardiovascular complications, compounded by the fact that they are often prescribed blood thinner medications which can exacerbate these risks. We analyzed the data to comprehensively understand the far-reaching impact and varied outcomes of underlying heart failure on patients diagnosed with autoimmune thrombocytopenic purpura.
Materials and Methods:The National Inpatient Sample database for 2019-2020 was utilized to identify individuals admitted with ITP. The cohort was further divided into patients with and without a secondary diagnosis of concomitant HF. Multivariate regression analysis was performed to evaluate the impact of HF on ITP patients and the outcomes.
Results:The study cohort consisted of 27885 patients hospitalized with ITP; among these patients, 1950 (7%) had the concurrent diagnosis of HF. Primary and secondary outcomes were analyzed after adjustment of confounding variables through multivariate regression analysis. There was no difference in Mortality (OR 1.1, 95% CI 0.52-2.29, P=0.795) and length of stay between the two patient groups (+1.14 days, 95% CI 0.32-1.95, P=0.006). However, the total cost of hospitalization increased significantly in patients with concurrent HF (+17762 USD, 95% CI 3439-35439, P=0.04). Patients with HF also had increased odds of acute respiratory failure (